[go: up one dir, main page]

DK3368085T5 - Modificerede alginater til anti-fibrotiske materialer og anvendelser - Google Patents

Modificerede alginater til anti-fibrotiske materialer og anvendelser Download PDF

Info

Publication number
DK3368085T5
DK3368085T5 DK16805919.4T DK16805919T DK3368085T5 DK 3368085 T5 DK3368085 T5 DK 3368085T5 DK 16805919 T DK16805919 T DK 16805919T DK 3368085 T5 DK3368085 T5 DK 3368085T5
Authority
DK
Denmark
Prior art keywords
applications
modified alginates
fibrotic
materials
fibrotic materials
Prior art date
Application number
DK16805919.4T
Other languages
English (en)
Other versions
DK3368085T3 (da
Inventor
Arturo Jose Vegas
Joshua Charles Doloff
Omid Veiseh
Minglin Ma
Robert S Langer
Daniel G Anderson
Original Assignee
Massachusetts Inst Technology
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Childrens Medical Ct Corp filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK3368085T3 publication Critical patent/DK3368085T3/da
Publication of DK3368085T5 publication Critical patent/DK3368085T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
DK16805919.4T 2015-11-01 2016-11-01 Modificerede alginater til anti-fibrotiske materialer og anvendelser DK3368085T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562249335P 2015-11-01 2015-11-01
PCT/US2016/059967 WO2017075631A1 (en) 2015-11-01 2016-11-01 Modified alginates for anti-fibrotic materials and applications

Publications (2)

Publication Number Publication Date
DK3368085T3 DK3368085T3 (da) 2024-04-02
DK3368085T5 true DK3368085T5 (da) 2024-09-30

Family

ID=57482494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16805919.4T DK3368085T5 (da) 2015-11-01 2016-11-01 Modificerede alginater til anti-fibrotiske materialer og anvendelser

Country Status (10)

Country Link
US (4) US10709818B2 (da)
EP (1) EP3368085B1 (da)
DK (1) DK3368085T5 (da)
ES (1) ES2978718T3 (da)
MX (1) MX2018005420A (da)
NZ (1) NZ742800A (da)
RU (1) RU2018120104A (da)
SG (1) SG11201803342RA (da)
WO (1) WO2017075631A1 (da)
ZA (1) ZA201802580B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ742800A (en) * 2015-11-01 2019-03-29 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
KR102558416B1 (ko) * 2015-11-01 2023-07-24 메사추세츠 인스티튜트 오브 테크놀로지 개선된 특성을 가진 물질
US10730983B2 (en) 2016-06-13 2020-08-04 Massachusetts Institute Of Technology Biocompatible coatings and hydrogels for reducing foreign body response and fibrosis
US11945786B2 (en) 2016-10-03 2024-04-02 Sigilon Therapeutics, Inc. Compounds, devices, and uses thereof
US11634512B2 (en) 2017-01-27 2023-04-25 Cornell University Zwitterionically modified polymers and hydrogels
US20180353650A1 (en) 2017-06-13 2018-12-13 Massachusetts Institute Of Technology Biocompatible microfabricated macrodevices for transplanting cells
US11318231B2 (en) 2017-11-06 2022-05-03 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants
US12162994B2 (en) 2018-03-02 2024-12-10 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
AU2019226587A1 (en) 2018-03-02 2020-09-03 Sigilon Therapeutics, Inc. Afibrotic compounds, devices, and uses thereof
BR112020020084A2 (pt) 2018-04-04 2021-01-05 Sigilon Therapeutics, Inc. Partícula, preparação de uma pluralidade de partículas, método de preparação de uma partícula, e, composição de partículas.
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2020023957A1 (en) * 2018-07-27 2020-01-30 Washington University Cell-embedded vascular graft for transplantation
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
SG11202108790SA (en) 2019-02-15 2021-09-29 Univ Rice William M Vascularizing devices and methods for implanted diagnostics and therapeutics
WO2022060459A1 (en) 2020-09-18 2022-03-24 Massachusetts Institute Of Technology High-throughput method to rapidly add chemical moieties to a small molecule library
CN112349961B (zh) * 2020-11-12 2021-09-24 宁德新能源科技有限公司 电解液及包含其的电化学装置和电子设备
WO2022140195A1 (en) * 2020-12-22 2022-06-30 William Marsh Rice University Implantable constructs for modulating an immune response
WO2022201181A1 (en) * 2021-03-24 2022-09-29 Indian Council Of Medical Research RT-LAMP ASSAY FOR DETECTION OF HUMAN β-ACTIN HOUSEKEEPING GENE
JP2025503454A (ja) * 2021-12-17 2025-02-04 ウィリアム マーシュ ライス ユニバーシティ Ｉｌ－１２を発現するカプセル化細胞及びその使用
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
WO2023235884A1 (en) 2022-06-03 2023-12-07 Flagship Pioneering Innovations Vi, Llc Compositions and methods
CN119546647A (zh) 2022-07-01 2025-02-28 西吉隆医疗股份有限公司 共价光交联多糖及其使用方法
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
US20240197932A1 (en) * 2022-12-20 2024-06-20 Plus Therapeutics, Inc. Biodegradable Alginate Microspheres
WO2024191428A1 (en) 2023-03-14 2024-09-19 Sigilon Therapeutics, Inc. Hydrogel capsules comprising covalently photocrosslinked polysaccharides and islet cells

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB676618A (en) 1947-09-12 1952-07-30 Kelco Co Alkylene glycol esters of alginic acid
GB768309A (en) 1954-03-27 1957-02-13 Henkel & Cie Gmbh Process for the production of amides of alginic acid
US2860130A (en) 1954-11-01 1958-11-11 Kelco Co Methyl alginate
US2881161A (en) 1955-03-25 1959-04-07 Henkel & Cie Gmbh Amides of alginic acid
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
IT1203814B (it) 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5605835A (en) 1988-05-23 1997-02-25 Regents Of The University Of Minnesota Bioreactor device with application as a bioartificial liver
JPH05502863A (ja) 1989-12-05 1993-05-20 トランセル・コーポレイション 生体内適用および埋め込み用コーティング組成物同種グルロン酸―アルギン酸塩およびその使用方法
US5821121A (en) 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
US5876452A (en) 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US5273904A (en) 1992-03-18 1993-12-28 Cobe Laboratories, Inc. Apparatus for purifying islets of Langerhans
FR2699545B1 (fr) 1992-12-18 1995-01-27 Oreal Agent gélifiant résultant de l'association d'un chitosane et d'un alginate d'alkyle ou d'hydroxyalkyle et son utilisation dans la préparation de compositions cosmétiques et pharmaceutiques.
EP2025353A2 (en) 1993-04-30 2009-02-18 Massachusetts Institute of Technology Injectable polysaccharide-cell compositions
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6171232B1 (en) 1997-06-26 2001-01-09 Cordis Corporation Method for targeting in vivo nitric oxide release
US6287558B1 (en) * 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6159531A (en) 1999-08-30 2000-12-12 Cardiovasc, Inc. Coating having biological activity and medical implant having surface carrying the same and method
US6932894B2 (en) 2001-05-15 2005-08-23 Therasense, Inc. Biosensor membranes composed of polymers containing heterocyclic nitrogens
US6977138B2 (en) 2001-07-24 2005-12-20 Massachusetts Institute Of Technology Reactive polymer coatings
US20030068308A1 (en) * 2001-10-09 2003-04-10 Jacek Rozga Intrasplenic encapsulated cell therapy
US20030113478A1 (en) 2001-12-12 2003-06-19 Dang Mai Huong Surface coating method and coated device
CN101851441A (zh) 2002-03-08 2010-10-06 瓦尔斯帕供应公司 具有低挥发性有机化合物含量的涂料
US7008476B2 (en) 2003-06-11 2006-03-07 Az Electronic Materials Usa Corp. Modified alginic acid of alginic acid derivatives and thermosetting anti-reflective compositions thereof
US20050056026A1 (en) * 2003-09-16 2005-03-17 Sundhar Shaam Periyapatna Personal cooling system
CA2549404A1 (en) * 2003-12-04 2005-06-23 Regents Of The University Of Minnesota Compositions and methods for the treatment of lysosomal storage disorders
US7329531B2 (en) 2003-12-12 2008-02-12 Scimed Life Systems, Inc. Blood-tight implantable textile material and method of making
US20060286141A1 (en) 2003-12-15 2006-12-21 Campbell Todd D Systems for gel-based medical implants
MXPA06006930A (es) 2003-12-23 2007-01-26 Fmc Biopolymer As Uso de matrices de alginato para controlar la proliferacion celular.
ITMI20041373A1 (it) 2004-07-09 2004-10-09 Lima Lto S P A N-metil-ammidi di carbossimetilcellulosa acido alginico o carbossimetalamido
BRPI0517800A (pt) 2004-11-12 2008-10-21 Fmc Biopolymer As processo para preparar um polìmero de alginato modificado, polìmero de alginato modificado, e, gel ou fibra de alginato
DE102005008434A1 (de) 2005-02-24 2006-09-07 Forschungszentrum Jülich GmbH Verfahren zur Modifizierung eines Substrats
ES2377479T3 (es) 2005-09-27 2012-03-28 Universite Joseph Fourier - Grenoble 1 Hidrogel funcionalizado con una porción polimerizable y sus utilizaciones como biosensores o biorreactores.
DE102005049833A1 (de) 2005-10-14 2007-04-19 Beiersdorf Ag Hydrophob modifizierte Alginate
AU2006326405B2 (en) * 2005-12-13 2013-10-31 President And Fellows Of Harvard College Scaffolds for cell transplantation
FR2894585B1 (fr) 2005-12-14 2012-04-27 Rhodia Recherches Et Tech Copolymere comprenant des unites zwitterioniques et d'autres unites, composition comprenant le copolymere, et utilisation
US8211361B2 (en) 2007-03-26 2012-07-03 Board Of Regents, The University Of Texas System N-halamine-based rechargeable biofilm-controlling tubular devices, method of making and using
KR20100063744A (ko) 2007-08-28 2010-06-11 에프엠씨 코포레이션 지연된 자가-겔화 알기네이트 시스템 및 이의 용도
US7998524B2 (en) 2007-12-10 2011-08-16 Abbott Cardiovascular Systems Inc. Methods to improve adhesion of polymer coatings over stents
EP2127689A1 (en) 2008-05-27 2009-12-02 RevisiOs B.V. i.o. Novel homogenous osteoinductive nanocomposites
CN101565469B (zh) 2008-10-28 2011-05-11 中国海洋大学 酰胺接枝的海藻酸钠纳米材料及其制备方法与应用
CA2745307A1 (en) 2008-12-12 2010-06-17 University Of Massachusetts Polyesters with grafted zwitterions
JP2012517284A (ja) 2009-02-09 2012-08-02 セント ジュード メディカル インコーポレイテッド 医療デバイスの生体適合性の向上
WO2010096649A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
ES2963295T3 (es) 2010-07-12 2024-03-26 Univ Southern California Sustrato biocompatible para facilitar las interconexiones entre células madre y tejidos diana y métodos para implantarlo
EP3354665B9 (en) * 2011-06-02 2022-08-03 Massachusetts Institute of Technology Modified alginates for cell encapsulation and cell therapy
WO2013086419A1 (en) 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
JP5963130B2 (ja) 2012-02-16 2016-08-03 学校法人同志社 生体組織補強材料キット及び生体組織補強材料
EP2672269A1 (en) 2012-06-07 2013-12-11 Solarwell Enhanced affinity ligands
SE537635C2 (sv) 2012-09-18 2015-08-25 Corticalis As Metod för att producera en alginatbelagd titandioxidscaffold, denna titandioxidscaffold samt medicinskt implantatinnefattande scaffolden
DE102012217078B4 (de) 2012-09-21 2015-03-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zum Herstellen einer photovoltaischen Solarzelle
US9788765B2 (en) 2012-09-28 2017-10-17 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US20150368713A1 (en) 2013-02-01 2015-12-24 THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
US9695275B2 (en) 2013-10-09 2017-07-04 The University Of Akron Integrated zwitterionic conjugated polymers for bioelectronics, biosensing, regenerative medicine, and energy applications
WO2015187204A1 (en) 2014-06-06 2015-12-10 Nanovault Medical, Llc Implantable cellular and biotherapeutic agents delivery canister
KR102719485B1 (ko) * 2014-08-01 2024-10-21 메사추세츠 인스티튜트 오브 테크놀로지 항-섬유 물질 및 응용을 위한 변형된 알기네이트
US20170014776A1 (en) 2015-07-13 2017-01-19 National University Of Singapore Anti-fouling membranes
NZ742800A (en) * 2015-11-01 2019-03-29 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
US11660029B2 (en) 2016-05-19 2023-05-30 Vivachek Biotech (Hangzhou) Co., Ltd Electrochemical electrode, continuous glucose monitoring sensor and preparation method therefor

Also Published As

Publication number Publication date
US10709818B2 (en) 2020-07-14
MX2018005420A (es) 2018-06-06
US20170226232A1 (en) 2017-08-10
RU2018120104A (ru) 2019-12-02
US20190184067A1 (en) 2019-06-20
US11090413B2 (en) 2021-08-17
RU2018120104A3 (da) 2019-12-02
EP3368085B1 (en) 2024-01-03
WO2017075631A1 (en) 2017-05-04
ZA201802580B (en) 2020-02-26
US20170239397A1 (en) 2017-08-24
SG11201803342RA (en) 2018-05-30
EP3368085A1 (en) 2018-09-05
US10729818B2 (en) 2020-08-04
DK3368085T3 (da) 2024-04-02
ES2978718T3 (es) 2024-09-18
US12097307B2 (en) 2024-09-24
NZ742800A (en) 2019-03-29
US20220031913A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
DK3368085T5 (da) Modificerede alginater til anti-fibrotiske materialer og anvendelser
IL250277B (en) Modified alginates for anti-fibrosis materials and applications
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3310371T3 (da) Glucagon og GLP-1-Co-agonistforbindelser
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3256468T3 (da) Tricykliske forbindelser og anvendelser deraf i lægemidler
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
DK3224603T3 (da) Nordning og fremgangsmåde til materialekarakteristik
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3322430T3 (da) Antiinflammatoriske peptider, og anvendelser deraf
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3098281T3 (da) Sammensætning omfattende hfc og hfo
DK3256479T3 (da) 4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3231793T3 (da) Dihydropyromidin-2-on-forbindelser og medicinske anvendelser deraf